Technical Data Sheet

Recombinant human FGF-19 protein

bioxcell.com

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***

Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Shelf Life

This product has a guaranteed shelf-life of one year from the date of customer receipt when stored as recommended.

Product Information

Catalog Number:	**RP086**
Protein Identity:	Confirmed identity with expected mass, determined by mass spectrometry
Reported Applications:	Metabolic disease research Liver cell regeneration Cancer research including gastrointestinal cancers Directed osteogenic differentiation of mesenchymal stem cells
Formulation:	Lyophilized, white powder
Endotoxin:	≤0.5 EU/mg, LAL assay
Purity:	≥95%; SDS-PAGE
Reconstitution:	Resuspend in sterile-filtered water at >50 µg/ml. Once reconstituted, store in single-use aliquots to avoid freeze-thaw cycles. Store reconstituted protein at -20 °C to -80 °C for a maximum of 12 months or until the expiry date if sooner.
Sterility:	Sterile
Production:	Microbial. Expressed in E. coli
Molecular Weight:	21.8 kDa (monomer)
Bioactivity Assay:	No significant difference between EC50 of reference and test lots
Mycoplasma:	Negative

Description

Recombinant human FGF-19 protein (fibroblast growth factor 19) is a 25 kDa member of the fibroblast growth factor family, produced primarily in the ileum in response to bile acids, that regulates bile acid homeostasis, glucose metabolism and lipid regulation. FGF-19 shares the core beta-trefoil fold of other FGFs, formed by anti-parallel beta-sheets, and binds FGFR4 together with the beta-Klotho co-receptor in target tissues such as the liver, an interaction that favors metabolic functions over the cell proliferation characteristic of other FGFs. Lacking the conventional heparin-binding domain, FGF-19 acts in an endocrine-like manner, circulating to act distally from its site of production. In obesity and type 2 diabetes, FGF-19 reduces hepatic glucose production and enhances insulin sensitivity, and its role in cholesterol metabolism makes it a candidate for non-alcoholic fatty liver disease (NAFLD) and primary bile acid disorders. Recombinant FGF-19 is used in studies of metabolic syndrome, liver disease and cancer, including efforts to improve liver function and reduce inflammation in cirrhosis and NAFLD, making it a key reagent for metabolic and liver disease research. This protein is optimized for in vivo and functional applications: low-endotoxin, tag-free, and carrier-free, supporting reproducible performance in demanding preclinical and bioactivity studies. A GMP-grade version of this protein is available for cell and gene therapy manufacturing. Contact us at customerservice@bioxcell.com for details. Species reactivity: human. Species similarity: mouse - 51%, rat - 52%, bovine - 75%, porcine - 77%.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at

https://bioxcell.com/faqs.

Store lyophilized protein between -20 °C and -80 °C until the date of expiry. Avoid freeze-thaw cycles

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © Bio X Cell, LLC